Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11976MR)

This product GTTS-WQ11976MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11976MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3229MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ13101MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ8067MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ6410MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ11043MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ14994MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ5117MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ13345MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06801591
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW